0.7447
price down icon0.72%   -0.0054
after-market After Hours: .78 0.0353 +4.74%
loading
Equillium Inc stock is traded at $0.7447, with a volume of 323.78K. It is down -0.72% in the last 24 hours and down -13.89% over the past month. Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
See More
Previous Close:
$0.7501
Open:
$0.722
24h Volume:
323.78K
Relative Volume:
1.70
Market Cap:
$26.38M
Revenue:
$42.62M
Net Income/Loss:
$-8.32M
P/E Ratio:
-1.4051
EPS:
-0.53
Net Cash Flow:
$-15.77M
1W Performance:
-45.84%
1M Performance:
-13.89%
6M Performance:
-55.41%
1Y Performance:
+48.94%
1-Day Range:
Value
$0.7005
$0.76
1-Week Range:
Value
$0.68
$1.50
52-Week Range:
Value
$0.45
$3.25

Equillium Inc Stock (EQ) Company Profile

Name
Name
Equillium Inc
Name
Phone
(858) 412-5302
Name
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Name
Employee
45
Name
Twitter
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
EQ's Discussions on Twitter

Equillium Inc Stock (EQ) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-29-21 Resumed Stifel Buy
Sep-15-21 Initiated Cantor Fitzgerald Overweight
Jul-14-20 Reiterated H.C. Wainwright Buy
Jul-10-20 Resumed Stifel Buy
Feb-22-19 Initiated SVB Leerink Outperform

Equillium Inc Stock (EQ) Latest News

pulisher
Nov 02, 2024

Equillium says Ono not acquiring itolizumab, stock craters 36% - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Ono says no to Equillium’s itolizumab - The Pharma Letter

Nov 01, 2024
pulisher
Nov 01, 2024

Jones Trading Downgrades Equillium (EQ) - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Equillium retains rights to itolizumab after Ono's option expires - Investing.com India

Nov 01, 2024
pulisher
Oct 31, 2024

Equillium shares downgraded to hold from buy By Investing.com - Investing.com Canada

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium shares downgraded to hold from buy - Investing.com India

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium keeps equilibrium in GVHD after Ono no-go - BioWorld Online

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium says Ono not acquiring itolizumab, stock craters 36% (NASDAQ:EQ) - Seeking Alpha

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium Maintains Rights to Itolizumab Following Ono Partnership - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium COO Christine Zedelmayer sells $18,750 in stock - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium COO Christine Zedelmayer sells $18,750 in stock By Investing.com - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Insider Sale: Sr. Vice President and COO Christine Zedelmayer Se - GuruFocus.com

Oct 31, 2024
pulisher
Oct 19, 2024

Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World

Oct 19, 2024
pulisher
Oct 13, 2024

Renaissance Technologies LLC Acquires 91,200 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World

Oct 13, 2024
pulisher
Oct 07, 2024

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - StockTitan

Oct 07, 2024
pulisher
Sep 27, 2024

Equillium CFO Jason Keyes sells $8,100 in company stock By Investing.com - Investing.com South Africa

Sep 27, 2024
pulisher
Sep 27, 2024

Equillium CFO Jason Keyes sells $8,100 in company stock - Investing.com India

Sep 27, 2024
pulisher
Sep 26, 2024

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop - Simply Wall St

Sep 26, 2024
pulisher
Sep 22, 2024

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Sep 22, 2024
pulisher
Sep 18, 2024

Equillium executive sells $32,985 in stock - Investing.com India

Sep 18, 2024
pulisher
Sep 17, 2024

Equillium executive sells $32,985 in stock By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

Equillium collaborates with Vivtex for oral formulation of autoimmune therapy - Yahoo Finance

Sep 17, 2024
pulisher
Sep 16, 2024

Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy - ForexTV.com

Sep 16, 2024
pulisher
Sep 10, 2024

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - StockTitan

Sep 10, 2024
pulisher
Sep 04, 2024

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 04, 2024
pulisher
Sep 02, 2024

Wall Street analysts’ outlook for Equillium Inc (EQ) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Equillium Inc’s Market Journey: Closing Weak at 1.07, Down -0.93 - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

How should investors view Equillium Inc (EQ)? - US Post News

Sep 02, 2024
pulisher
Aug 30, 2024

Equillium Inc Inc. (EQ) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Aug 30, 2024
pulisher
Aug 28, 2024

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan

Aug 28, 2024
pulisher
Aug 28, 2024

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26 - Business Wire

Aug 28, 2024
pulisher
Aug 21, 2024

Q3 2024 Earnings Forecast for Equillium, Inc. (NASDAQ:EQ) Issued By HC Wainwright - Defense World

Aug 21, 2024
pulisher
Aug 20, 2024

Equillium, Inc. (NASDAQ:EQ) Forecasted to Post FY2024 Earnings of $0.62 Per Share - Defense World

Aug 20, 2024
pulisher
Aug 19, 2024

Equillium’s (EQ) Buy Rating Reiterated at HC Wainwright - Defense World

Aug 19, 2024
pulisher
Aug 14, 2024

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience - Marketscreener.com

Aug 14, 2024
pulisher
Aug 11, 2024

Equillium Second Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Aug 11, 2024
pulisher
Aug 10, 2024

Equillium (NASDAQ:EQ) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - Defense World

Aug 10, 2024
pulisher
Aug 09, 2024

EQEquillium, Inc. Latest Stock News & Market Updates - StockTitan

Aug 09, 2024
pulisher
Aug 08, 2024

Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates - MSN

Aug 08, 2024
pulisher
Aug 08, 2024

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights - StockTitan

Aug 08, 2024
pulisher
Aug 07, 2024

Equillium Inc (EQ) Stock: The Story of a 52-Week Stock Range - The InvestChronicle

Aug 07, 2024
pulisher
Aug 06, 2024

Equillium's itolizumab advances in phase 3 aGVHD trial - Investing.com

Aug 06, 2024
pulisher
Aug 06, 2024

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease - StockTitan

Aug 06, 2024
pulisher
Jul 29, 2024

Acadian Asset Management LLC Acquires New Holdings in Equillium, Inc. (NASDAQ:EQ) - Defense World

Jul 29, 2024
pulisher
Jul 24, 2024

Equillium faces delisting risk, Nasdaq warns on bid price - Investing.com India

Jul 24, 2024
pulisher
Jul 24, 2024

Equillium faces delisting risk, Nasdaq warns on bid price By Investing.com - Investing.com Canada

Jul 24, 2024
pulisher
Jul 18, 2024

Equillium CFO Jason Keyes sells shares worth $8,700 - Investing.com

Jul 18, 2024
pulisher
Jul 18, 2024

Equillium reports $33.3 million in cash and investments By Investing.com - Investing.com

Jul 18, 2024
pulisher
Jul 18, 2024

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance - StockTitan

Jul 18, 2024

Equillium Inc Stock (EQ) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Equillium Inc Stock (EQ) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Zedelmayer Christine
Sr. Vice President and COO
Oct 28 '24
Sale
1.25
15,000
18,750
135,246
Tom Penny
Principal Accounting Officer
Oct 28 '24
Sale
1.25
2,835
3,544
6,533
Tom Penny
Principal Accounting Officer
Oct 25 '24
Sale
1.25
683
854
9,368
Keyes Jason A
Chief Financial Officer
Sep 26 '24
Sale
0.81
10,000
8,100
57,720
Tom Penny
Principal Accounting Officer
Sep 16 '24
Sale
0.85
38,806
32,985
10,051
Keyes Jason A
Chief Financial Officer
Jul 16 '24
Sale
0.87
10,000
8,700
67,720
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):